

2689-957  
WALTER PÖLDINGER  
FRANÇOIS WIDER

# INDEX PSYCHOPHARMACORUM

7th revised and expanded edition  
7., überarbeitete und erweiterte Auflage  
7<sup>e</sup> édition revue et augmentée  
7<sup>a</sup> edizione rielaborata e ampliata  
7<sup>a</sup> reeditada y ampliada edición



HANS HUBER  
BERN STUTTGART TORONTO

# TABLE OF CONTENTS

Abbreviations . . . . .	9
Preface . . . . .	11
Vorwort . . . . .	12
Préface . . . . .	13
Prefazione . . . . .	14
Prólogo . . . . .	15
1. Neuroleptics . . . . .	17
1.1. Rauwolfia Alkaloids . . . . .	17
1.2. Benzoquinolizine Derivatives . . . . .	20
1.3. Phenothiazine Derivatives . . . . .	21
1.3.1. Aminoalkylphenothiazine Derivatives . . . . .	21
1.3.2. Piperidylalkylphenothiazine Derivatives . . . . .	30
1.3.3. Piperazinylalkylphenothiazine Derivatives . . . . .	35
1.3.4. Homopiperazinylalkylphenothiazine Derivatives . . . . .	45
1.3.5. Other Phenothiazine Derivatives . . . . .	45
1.4. Azaphenothiazine Derivatives . . . . .	46
1.5. Thioxanthene Derivatives . . . . .	47
1.6. Butyrophenone Derivatives . . . . .	50
1.7. Diphenylbutylpiperidine Derivatives . . . . .	57
1.8. Dibenzothiepine Derivatives . . . . .	58
1.9. Dibenzodiazepine Derivatives . . . . .	60
1.10. Dibenzothiazepine Derivatives . . . . .	60
1.11. Dibenzoxazepine Derivatives . . . . .	61
1.12. Indole Derivatives . . . . .	61
1.13. Benzamides . . . . .	62
2. Tranquilizers . . . . .	67
2.1. Glycerol Derivatives . . . . .	67
2.2. Propanediol Derivatives . . . . .	71
2.3. Carbamates . . . . .	75
2.4. Alkinols . . . . .	77
2.5. Urea Derivatives . . . . .	78
2.6. Diphenylmethane Derivatives . . . . .	79
2.7. Benzodiazepine Derivatives . . . . .	85
2.7.1. Benzodiazepinereceptor Agonists . . . . .	85
2.7.2. Benzodiazepinereceptor Antagonists . . . . .	113
2.8. Non-Benzodiazepine Anxiolytics . . . . .	113
2.9. Various Tranquilizers . . . . .	114
2.10. Barbituric Acid Derivatives . . . . .	118

3.	Hypnotics . . . . .	119
3.1.	Non-Benzodiazepine Hypnotics . . . . .	119
4.	Beta-Receptor Blockers . . . . .	121
5.	Antidepressants . . . . .	139
5.1.	Tricyclic Antidepressants . . . . .	139
5.1.1.	Dibenzazepine Derivatives . . . . .	139
5.1.2.	Dibenzodiazepine Derivatives . . . . .	144
5.1.3.	Dibenzocycloheptene Derivatives . . . . .	145
5.1.3.1.	Dibenzocycloheptadiene Derivatives . . . . .	145
5.1.3.2.	Dibenzocycloheptatriene Derivatives . . . . .	148
5.1.4.	Dibenzothiepine Derivatives . . . . .	150
5.1.5.	Dibenzothiazepine Derivatives . . . . .	150
5.1.6.	Dibenzoxepine Derivatives . . . . .	151
5.1.7.	Dibenzoxazepine Derivatives . . . . .	152
5.1.8.	Anthracene Derivatives . . . . .	152
5.1.9.	Acridane Derivatives . . . . .	153
5.1.10.	Indole Derivatives . . . . .	154
5.2.	Tetracyclic Antidepressants . . . . .	154
5.2.1.	Dibenzobicyclooctadiene Derivatives . . . . .	154
5.2.2.	Various Tetracyclic Antidepressants . . . . .	155
5.3.	Non-Tricyclic Antidepressants . . . . .	156
5.3.1.	Selective 5-HT Uptake Inhibitors . . . . .	156
5.3.2.	5-HT Precursors . . . . .	157
5.3.3.	Various Non-Tricyclic Antidepressants . . . . .	159
6.	Bisleptics . . . . .	164
7.	MAO Inhibitors . . . . .	165
7.1.	Non-Selective MAO Inhibitors . . . . .	165
7.1.1.	Hydrazine Derivatives . . . . .	165
7.1.2.	Cyclopropylamine Derivatives . . . . .	169
7.1.3.	Propargylamine Derivatives . . . . .	169
7.1.4.	Indole Derivatives . . . . .	170
7.1.5.	Various Non-Selective MAO Inhibitors . . . . .	170
7.2.	Selective MAO Inhibitors . . . . .	171
7.2.1.	Selective MAO-A Inhibitors . . . . .	171
7.2.2.	Selective MAO-B Inhibitors . . . . .	171
8.	Lithium Salts . . . . .	172
9.	Psychostimulants . . . . .	176
9.1.	Phenylethylamine Derivatives . . . . .	176
9.2.	Dimethylaminoethanol (DMAE) Derivatives . . . . .	198
9.3.	Various Psychostimulants . . . . .	202

10.	Cerebroactive Substances . . . . .	207
10.1.	Alkaloids . . . . .	207
10.1.1.	Ergot Derivatives . . . . .	207
10.1.2.	Vincamine Derivatives . . . . .	210
10.2.	Piracetam Derivatives . . . . .	214
10.3.	Cholinergic Agents . . . . .	215
10.3.1.	Acetylcholine Precursors . . . . .	215
10.3.2.	Acetylcholinesterase Inhibitors . . . . .	217
10.4.	Vasodilators/Haemorheological Agents . . . . .	218
10.5.	Antianoxic Substances . . . . .	220
10.6.	Vitamine Type Compounds . . . . .	221
10.7.	Various Cerebroactive Substances . . . . .	223
11.	Valeric Acid Derivatives . . . . .	226
12.	GABA-mimetics . . . . .	229
13.	Various Psychotropic Substances . . . . .	230
14.	Combination Preparations . . . . .	233
15.	Appendix: Investigational Drugs . . . . .	241
15.1.	Neuroleptics (Antipsychotics) . . . . .	241
15.2.	Tranquilizers . . . . .	246
15.3.	Beta-Receptor-Blockers . . . . .	249
15.4.	Antidepressants . . . . .	251
15.5.	Selective MAO Inhibitors . . . . .	258
15.6.	Cerebroactive Substances . . . . .	259
15.7.	GABA-mimetics . . . . .	263
15.8.	Various Psychotropic Drugs . . . . .	264
	Addendum . . . . .	266
	Acknowledgments . . . . .	267
	Literature . . . . .	269
	Alphabetical Index . . . . .	271